Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xenomics has granted Asuragen co-exclusive worldwide rights to incorporate NPM1 technology into its molecular diagnostic products.
Subscribe to our email newsletter
Under the terms of this agreement, Asuragen will have the right to develop, manufacture and market products for the diagnosis, stratification and monitoring of patients with Acute Myeloid Leukemia (AML).
Rollie Carlson, president of Asuragen, said: “Adding NPM1 mutation testing to the treating physician’s testing arsenal will enable physicians and patients to make more informed choices in the treatment of AML. NPM1 testing complements Asuragen’s current leukemia products and we continue in our dedication to bring leading-edge leukemia diagnostic products such as NPM1 testing to the AML community.”